Vaccination with minigenes encoding VH-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing b cells and inhibit lupus

Journal of Experimental Medicine

Volumn 196, Issue 6, 2002, Pages 731-741

  Fan, Guo Chang ^a   Singh, Ram Raj ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Animal models; Peptides; Systemic lupus erythematosus; T cell epitopes; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; DNA ANTIBODY; DOUBLE STRANDED DNA; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 13; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PLASMID DNA; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; LUPUS ERYTHEMATOSUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; COMPUTATIONAL BIOLOGY; CYTOKINES; DNA; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0037120006     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020223     Document Type: Article

References (55)

1. Chan, O.T., M.P. Madaio, and M.J. Shlomchik. 1999. B cells are required for lupus nephritis in the polygenic, Fasintact MRL model of systemic autoimmunity. J. Immunol. 163: 3592-3596.
2. Singh, R.R., A.N. Malaviya, R. Sindhwani, R. Malaviya, and S.D. Khare. 1988. Cyclophosphamide pulse therapy in SLE: Effect on clinical activity and lymphocyte subsets. New Engl. Reg. Allergy Proc. 9:479 (Abstr.).
3. Spatz, L., A. Iliev, V. Saenko, L. Jones, M. Irigoyen, A. Manheimer-Lory, B. Gaynor, C. Putterman, M. Bynoe, C. Kowal, et al. 1997. Studies on the structure, regulation, and pathogenic potential of anti-dsDNA antibodies. Methods. 11: 70-78.
4. Ohnishi, K., F.M. Ebling, B. Mitchell, R.R. Singh, B.H. Hahn, and B.P. Tsao. 1994. Comparison of pathogenic and nonpathogenic murine antibodies to DNA: Antigen binding and structural characteristics. Int. Immunol. 6:817-830.
5. Theofilopoulos, A.N., R. Kofler, P.A. Singer, and F.J. Dixon. 1989. Molecular genetics of murine lupus models. Adv. Immunol. 46:61-109.
6. Tillman, D.M., N.-T. Jou, R.J. Hill, and T.N. Marion. 1992. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice. J. Exp. Med. 176:761-779.
7. Gangemi, R.M.R., A.K. Singh, and K.J. Barrett. 1993. Independently derived IgG anti-DNA autoantibodies from two lupus-prone mouse strains express a VH gene that is not present in most murine strains. J. Immunol. 151:4660-4671.
8. Ash-Lerner, A., M. Ginsberg-Strauss, Y. Pewzner-Jung, D.D. Desai, T.N. Marion, and D. Eilat. 1997. Expression of an anti-DNA-associated VH gene in immunized and autoimmune mice. J. Immunol. 159:1508-1519.
9. Singh, R.R., V. Kumar, F.M. Ebling, S. Southwood, A. Sette, E.E. Sercarz, and B.H. Hahn. 1995. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J. Exp. Med. 181:2017-2027.
10. Zhang, X., D.S. Smith, A. Guth, and L.J. Wysocki. 2001. A receptor presentation hypothesis for T cell help that recruits autoreactive B cells. J. Immunol. 166:1562-1571.
11. Singh, R.R., B.H. Hahn, B.P. Tsao, and F.M. Ebling. 1998. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J. Clin. Invest. 102:1841-1849.
12. Bartnes, K., and K. Hannestad. 1997. Engagement of the B lymphocyte antigen receptor induces presentation of intrinsic immunoglobulin peptides on major histocompatibility complex class II molecules. Eur. J. Immunol. 27:1124-1130.
13. Trojan, A., J.L. Schultze, M. Witzens, R.H. Vonderheide, M. Ladetto, J.W. Donovan, and J.G. Gribben. 2000. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6:667-672.
14. Weiss, S., and B. Bogen. 1989. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA. 86:282-286.
15. Yurin, V.L., A.Y. Rudensky, S.M. Mazel, and J.M. Blechman. 1989. Immunoglobulin-specific T-B cell interaction. II. T cell clones recognize the processed form of B cells' own surface immunoglobulin in the context of the major histocompatibility complex class II molecule. Eur. J. Immunol. 19: 1685-1691.
16. Weiss, S., and B. Bogen. 1991. MHC class II-restricted presentation of intracellular antigen. Cell. 64:767-776.
17. Krishnan, M.R., and T.N. Marion. 1998. Comparison of the frequencies of arginines in heavy chain CDR3 of antibodies expressed in the primary B-cell repertoires of autoimmuneprone and normal mice. Scand. J. Immunol. 48:223-232.
18. Alexander-Miller, M.A., K. Burke, U.H. Koszinowski, T.H. Hansen, and J.M. Connolly. 1993. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J. Immunol. 151:1-10.
19. Deng, Y., J.W. Yewdell, L.C. Eisenlohr, and J.R. Bennink. 1997. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1507-1515.
20. Addison, C.L., M. Hitt, D. Kunsken, and F.L. Graham. 1997. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78:1653-1661.
21. Lopez-Otin, C., C. Simon-Mateo, L. Martinez, and E. Vinuela. 1989. Gly-Gly-X, a novel consensus sequence for the proteolytic processing of viral and cellular proteins. J. Biol. Chem. 264:9107-9110.
22. Kozak, M. 1987. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15: 8125-8148.
23. Singh, R.R., B.H. Hahn, and E.E. Sercarz. 1996. Neonatal peptide exposure can prime T cells, and upon subsequent immunization induce their immune deviation: Implications for antibody vs. T cell-mediated autoimmunity. J. Exp. Med. 183:1613-1622.
24. van der Burg, S.H., MJ. Visseren, R.M. Brandt, W.M. Kast, and C.J. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308-3314.
25. Parker, K.C., M.A. Bednarek, and J.E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains. J. Immunol. 152:163-175.
26. Kuttler, C., A.K. Nussbaum, T.P. Dick, H.G. Rammensee, H. Schild, and K.P. Hadeler. 2000. An algorithm for the prediction of proteasomal cleavages. J. Mol. Biol. 298:417-429.
27. Keene, J.A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768-782.
28. Hanke, T., T.J. Blanchard, J. Schneider, C.M. Hannan, M. Becker, S.C. Gilbert, A.V. Hill, G.L. Smith, and A. McMichael. 1998. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:439-445.
29. Ulmer, J.B., T.M. Fu, R.R. Deck, A. Friedman, L. Guan, C. DeWitt, X. Liu, S. Wang, M.A. Liu, J.J. Donnelly, and M.J. Caulfield. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 259: 1745-1749.
30. Gilkeson, G.S., P. Ruiz, A.M. Pippen, A.L. Alexander, J.B. Lefkowith, and D.S. Pisetsky. 1996. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J. Exp. Med. 183:1389-1397.
31. Mor, G., M. Singla, A.D. Steinberg, S.L. Hoffman, K. Okuda, and D.M. Klinman. 1997. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 8:293-300.
32. - cells that make TH2 cytokines and help B cells. Science. 260: 1802-1805.
33. + respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J. Virol. 73:8944-8949.
34. + T cells. J. Immunol. 165:915-924.
35. Manheimer-Lory, A.J., G. Zandman-Goddard, A. Davidson, C. Aranow, and B. Diamond. 1997. Lupus-specific antibodies reveal an altered pattern of somatic mutation. J. Clin. Invest. 100:2538-2546.
36. Singh, R.R., F.M. Ebling, E.E. Sercarz, and B.H. Hahn. 1995. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J. Clin. Invest. 96:2990-2996.
37. Hahn, B.H., and F.M. Ebling. 1987. Idiotype restriction in murine lupus; high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice. J. Immunol. 138: 2110-2118.
38. Panosian-Sahakian, N., J.L. Klotz, F. Ebling, M. Kronenberg, and B. Hahn. 1989. Diversity of Ig V gene segments found in anti-DNA autoantibodies from a single (NZB x NZW)F1 mouse. J. Immunol. 142:4500-4506.
39. Chan, O.T., L.G. Hannum, A.M. Haberman, M.P. Madaio, and M.J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639-1648.
40. Wang, X., W. Huang, M. Mihara, J. Sinha, and A. Davidson. 2002. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J. Immunol. 168:2046-2053.
41. Kono, D.H., R.W. Burlingame, D.G. Owens, A. Kuramochi, R.S. Balderas, D. Balomenos, and A.N. Theofilopoulos. 1994. Lupus susceptibility loci in New Zealand mice. Proc. Natl. Acad. Sci. USA. 91:10168-10172.
42. Wakeland, E.K., K. Liu, R.R. Graham, and T.W. Behrens. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 15:397-408.
43. Waters, S.T., S.M. Fu, F. Gaskin, U.S. Deshmukh, S.S. Sung, C.C. Kannapell, K.S. Tung, S.B. McEwen, and M. McDuffie. 2001. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin. Immunol. 100:372-383.
44. Stohl, W., J.E. Elliott, L. Li, E.R. Podack, D.H. Lynch, and C.O. Jacob. 1997. Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin. Arthritis Rheum. 40:1130-1137.
45. + T suppressor cell function in patients with active systemic lupus erythematosus. J. Immunol. 166:6452-6457.
46. + T cells. J. Immunol. 155:609-618.
47. + T and NK cells. J. Exp. Med. 180:1937-1942.
48. Gaynor, B., C. Putterman, P. Valadon, L. Spatz, M.D. Scharff, and B. Diamond. 1997. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. USA. 94:1955-1960.
49. Waisman, A., PJ. Ruiz, E. Israeli, E. Eilat, S. Konen-Waisman, H. Zinger, M. Dayan, and E. Mozes. 1997. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. USA. 94:4620-4625.
50. Jouanne, C., S. Avrameas, and B. Payelle-Brogard. 1999. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBx-NZW)F1 mice. Immunology. 96:333-339.
51. Kaliyaperumal, A., M.A. Michaels, and S.K. Datta. 1999. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162:5775-5783.
52. Eilat, E., H. Zinger, A. Nyska, and E. Mozes. 2000. Prevention of systemic lupus erythematosus-like disease in (NZBx-NZW)F1 mice by treating with CDK1- and CDR3-based peptides of a pathogenic autoantibody. J. Clin. Immunol. 20: 268-278.
53. Hahn, B.H., R.R. Singh, W.K. Wong, B.P. Tsao, K. Bulpitt, and F.M. Ebling. 2001. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 44:432-441.
54. Eilat, E., M. Dayan, H. Zinger, and E. Mozes. 2001. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA autoantibody ameliorates experimental systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 98:1148-1153.
55. Singh, R.R. 2000. Potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr. Opin. Rheumatol. 12:399-406.